Randomized, Placebo-Controlled Trial of Rifaximin Therapy for Lowering Gut-Derived Cardiovascular Toxins and Inflammation in CKD.

Cassandra KimberShiqin ZhangCassandra JohnsonRaymond E WestAlexander J ProkopienkoJonathan D MahnkenAlan S YuAndrew N HoofnagleDiana IrCharles E RobertsonMakoto MiyazakiMichel ChoncholAnna JovanovichBryan KestenbaumDaniel N FrankThomas D NolinJason R Stubbs

Published in: Kidney360 (2020)

Rifaximin Therapy in Chronic Kidney Disease, NCT02342639.

Keyphrases

double blind
placebo controlled
irritable bowel syndrome
oxidative stress
clinical trial
chronic kidney disease
open label
phase iii
phase ii
study protocol
stem cells
cell therapy